TuHURA Biosciences, Inc./NV
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 06/30/24 | FY 12/31/23 | FY 06/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | — | $0 | — |
| Research and development | $20.5M | $13.3M | $2.7M | $9.4M | $9.3M |
| Operating expenses | $31.8M | $17.6M | $8.5M | $29.8M | $14.8M |
| Interest expense | $625,283 | $4.1M | — | $18,688 | — |
| Pretax income | -$30.1M | -$21.7M | — | $29.3M | — |
| Income tax expense | $1,600 | $3,768 | $0 | $0 | $0 |
| Net income | -$30.1M | -$21.7M | -$8.3M | -$29.3M | -$14.6M |
| Balance Sheet | |||||
| Cash and equivalents | $3.6M | $12.7M | $4.9M | $3.7M | $1.5M |
| Current assets | $4.6M | $19.6M | $5.5M | $4.2M | $3.3M |
| Total assets | $27.4M | $20.0M | $6.2M | $4.4M | $4.0M |
| Current liabilities | $5.9M | $5.3M | $2.3M | $3.6M | $3.1M |
| Total liabilities | $6.4M | $5.4M | $2.4M | $5.9M | $3.2M |
| Stockholders' equity | $20.9M | $14.6M | $3.8M | -$1.6M | $731,000 |
| Cash Flow Statement | |||||
| Cash from operations | -$27.6M | -$14.7M | -$7.2M | -$12.0M | -$11.9M |
| Depreciation and amortization | $71,265 | $116,710 | $55,000 | $177,377 | $60,000 |
| Stock-based compensation | $6.4M | $2.0M | $607,000 | $478,890 | $1.5M |
| Capital expenditure | $76,083 | $57,906 | $20,000 | $79,224 | $679,000 |
| Free cash flow | -$27.7M | -$14.8M | -$7.2M | -$12.0M | -$12.5M |
| Share repurchases | — | — | — | $24,751 | — |
Shares outstanding 63.7M · Free float 56.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.